Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

December 14, 2012

Primary Completion Date

April 26, 2016

Study Completion Date

May 20, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel, Reolysin and Prednisone

Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.

DRUG

Docetaxel and Prednisone

Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.

Trial Locations (11)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V2S 0C2

BCCA - Abbotsford Centre, Abbotsford

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

S4T 7T1

Allan Blair Cancer Centre, Regina

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oncolytics Biotech

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK

NCT01619813 - Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter